Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 16:00 ET
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
July 17, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to...
Exosome Diagnostics Achieves ISO 13485:2016 Certification
June 13, 2018 07:07 ET
|
Exosome Diagnostics
Waltham, MA, June 13, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced that it has achieved ISO 13485:2016 certification for their Munich location, upgraded from the ISO 13485:2003...
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
May 17, 2018 12:47 ET
|
Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
May 15, 2018 09:52 ET
|
Exosome Diagnostics
Waltham, MA, May 15, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. received great interest from their presentations at the International Society for Extracellular Vesicles (ISEV) 2018 in...
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
May 09, 2018 08:03 ET
|
Exosome Diagnostics
Waltham, MA, May 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx®...
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test
May 08, 2018 06:30 ET
|
Exosome Diagnostics
Waltham, MA, May 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has expanded its urology salesforce within the United States after a successful first quarter commercial launch of ExoDx...
Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
May 03, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at...
Exosome Diagnostics Obviates Tissue Biopsies
April 17, 2018 06:21 ET
|
Exosome Diagnostics
Waltham, MA, April 17, 2018 (GLOBE NEWSWIRE) -- This groundbreaking observation is presented as Late Breaking Research at the AACR Annual Meeting in Chicago on Tuesday by Dr Sudipto Chakrabortty....
Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs
March 21, 2018 07:41 ET
|
Exosome Diagnostics
Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs. As an internationally recognized...